INTRODUCTION {#s1}
============

Circulating sex hormone levels are associated with type 2 diabetes, but the causal nature of these associations is controversial. Many observational epidemiological studies have described associations between type 2 diabetes and androgens (primarily testosterone), estrogens (estradiol) and their circulating binding protein, sex hormone binding protein (SHBG) ([@DDP522C1]). Meta-analyses of these studies show consistent sex-specific associations. In men, lower testosterone, higher estradiol and lower SHBG levels are associated with type 2 diabetes. In women, higher testosterone, higher estradiol and lower SHBG are associated with type 2 diabetes ([@DDP522C1]).

The differences in sex hormone levels between type 2 diabetes patients and controls are complicated by increased adiposity, which is also associated with reduced SHBG. However, differences in adiposity cannot fully explain the associations between sex hormones and type 2 diabetes. In both men and women, the differences in testosterone, estradiol and SHBG levels between type 2 diabetes patients and non-diabetic individuals remain very similar before and after controlling for BMI, age, ethnic background and, in females, menopausal status ([@DDP522C1]).

There is evidence that the associations between sex hormones and type 2 diabetes may be causal. First, a recent study described an association between two SNPs in the *SHBG* gene and type 2 diabetes ([@DDP522C2]). Second, prospective studies show that the levels of sex hormones are altered in individuals diagnosed many years later ([@DDP522C1]). Third, hyper-androgenic disorders such as polycystic ovarian syndrome (PCOS) in women result in an increased risk of type 2 diabetes and are very strongly associated with insulin resistance ([@DDP522C3]). In men, androgen supplementation in the presence of central obesity and low testosterone levels increases insulin sensitivity ([@DDP522C4]--[@DDP522C6]). Fourth, male rats lacking the androgen receptor are insulin resistant ([@DDP522C7]) and female rats treated with testosterone after oophorectomy become insulin resistant ([@DDP522C8]), findings that are consistent with the sex-specific associations seen in humans.

Despite some evidence pointing towards a causal role of sex hormones in type 2 diabetes, further evidence is required. The recent genetic study involved a relatively small number of patients (359 women and 170 men), the effect sizes, with odds ratios (ORs) of 1.52 and 1.39, are similar to those for SNPs in the *TCF7L2* gene ([@DDP522C9]), which raises doubt as to why these associations were not found by genome-wide association approaches, and the evidence of association between *SHBG* SNPs and type 2 diabetes was not strong (*P* = 0.02 for each SNP under the best model) ([@DDP522C2]). It is well known that even well-conducted, well-controlled epidemiological associations can often be confounded by imperfect measurement of known, or unknown, related factors. Prospective studies establish whether or not a risk factor is present prior to disease diagnosis, but do not necessarily solve the concerns about epidemiological studies. Disease processes can start many years before disease diagnosis, which means that altered hormone levels observed prospectively could be a consequence rather than cause of early disease processes. The causal direction of the associations between hyper-androgenism and insulin resistance in PCOS is not known. Studies in animals may not be relevant to humans and human trials of androgen therapy have focused on people with extreme levels of obesity or circulating hormones and conflicting results have been reported ([@DDP522C10],[@DDP522C11]). Finally, insulin lowering interventions in non-diabetic men and women (without PCOS) lead to increased SHBG levels, suggesting that insulin can causally influence sex hormone dynamics ([@DDP522C12],[@DDP522C13]).

Genetic studies can be a valuable additional tool which help to dissect causal directions of epidemiological associations ([@DDP522C14]). In most situations, alleles at genetic variants are randomly distributed between individuals who differ by conventional confounding factors. This 'Mendelian randomization' principle has been used recently in the context of metabolic traits to provide evidence that lifelong exposure to slightly raised C-reactive protein (CRP) ([@DDP522C15]), Interleukin-18 (IL18) ([@DDP522C16]), regulated on activation, normal T-cell expressed and secreted protein (RANTES) ([@DDP522C17]) or beta-carotene ([@DDP522C18]) levels are unlikely to alter the risk of type 2 diabetes, whereas some evidence for an aetiological association has been suggested for macrophage migration inhibitory factor (MIF) ([@DDP522C19]). Other examples of this approach provide mechanistic insight to disease. For example the association between variation in the *FTO* gene, that is associated with adiposity, and some cancers, provides some evidence that adiposity has an aetiological role in cancer ([@DDP522C20]).

In this study, we used the principle of Mendelian Randomization to provide evidence for or against an aetiological role of raised SHBG levels and reduced risk of type 2 diabetes. Our results indicate that higher SHBG levels may reduce the risk of type 2 diabetes.

RESULTS {#s2}
=======

Observed association between *SHBG* SNP and type 2 diabetes risk {#s2a}
----------------------------------------------------------------

We observed evidence of association between the *SHBG* SNP rs1799941 and type 2 diabetes (OR 0.94, 95% CI: 0.91, 0.97; *P* = 2 × 10^−5^), with the SHBG raising allele associated with reduced risk of type 2 diabetes (Figs [1](#DDP522F1){ref-type="fig"} and [2](#DDP522F2){ref-type="fig"}). This result included correction for age, sex and BMI across 14 of the 15 studies (one study is uncorrected), but the result was similar when correcting for age and sex only (OR 0.94, 95% CI: 0.91, 0.97; *P* = 2 × 10^−5^). The result was also similar in men (OR 0.95, 95% CI: 0.91, 0.99; *P* = 0.009); and women (OR 0.93, 95% CI: 0.89, 0.98; *P* = 0.003). There was no evidence of heterogeneity in any analysis, either between or within sexes or with and without correction for BMI (all heterogeneity *P* \> 0.15, maximum I2---a measure of the variation in effect size attributable to heterogeneity---29%). There was a trend towards an increased effect in carriers of two copies of the SHBG raising allele, compared with carriers of two copies of the SHBG lowering allele (OR 0.91, 95% CI: 0.85, 0.97; *P* = 0.006) (uncorrected). The SHBG lowering (G) allele at rs1799941 ranged in allele frequency from 0.72 to 0.75 in individual study controls and from 0.73 to 0.77 in individual study type 2 diabetes patients.

![Triangulation approach to assess how the observed association of the *SHBG* SNP rs1799941 with type 2 diabetes compares with that expected given the association between rs1799941 and circulating SHBG levels and the difference in SHBG levels between type 2 diabetes patients and controls.](ddp52201){#DDP522F1}

![Meta-analysis of rs1799941 in type 2 diabetes case--control studies correcting for or matching for BMI, age and sex. OR, odds ratio.](ddp52202){#DDP522F2}

Observed differences in SHBG levels between type 2 diabetes patients and controls {#s2b}
---------------------------------------------------------------------------------

Details of the differences in SHBG levels between type 2 diabetes patients and controls are given in Table [2](#DDP522TB2){ref-type="table"} and in Figures [1](#DDP522F1){ref-type="fig"} and [3](#DDP522F3){ref-type="fig"}. SHBG levels were 0.233 (95% CI: −0.35, −0.115) standard deviations lower in type 2 diabetes patients compared with controls, when controlling for BMI. This estimate differed little between men (OR −0.218, 95% CI: −0.360, −0.076) and women (OR −0.264, 95% CI: −0.475, −0.054).

![Details of the correlations between SHBG levels and type 2 diabetes from seven cross-sectional studies of European individuals correcting or matching for BMI or waist circumference.](ddp52203){#DDP522F3}

Approximate expected association between *SHBG* SNP and type 2 diabetes risk {#s2c}
----------------------------------------------------------------------------

We next tested whether or not the observed association between the *SHBG* SNP and type 2 diabetes was consistent with that expected if SHBG levels alter the risk of type 2 diabetes. We used the estimates of the effect of rs1799941 on circulating SHBG levels and the difference in SHBG levels between type 2 diabetes patients and controls to calculate an approximate expected effect of rs1799941 with type 2 diabetes (Fig. [1](#DDP522F1){ref-type="fig"}). The expected associations were: for men and women combined (OR 0.92, 95% CI: 0.88, 0.96); for men (OR 0.92, 95% CI: 0.88, 0.97); and for women (OR 0.91, 95% CI: 0.84, 0.98). These estimates were similar to those observed.

Associations between SHBG SNPs and type 2 diabetes related intermediate traits {#s2d}
------------------------------------------------------------------------------

We did not detect any association between the *SHBG* SNP rs1799941 (or its close proxy rs12150660) and any measures of intermediate type 2 diabetes related traits in population-based studies. These included fasting insulin (*P* = 0.11, *N* = 37 864), the HOMAIR measure of insulin resistance (*P* = 0.24, *N* = 36 601), fasting glucose (*P* = 0.52, *N* = 45 691), the HOMAB measure of beta-cell function (*P* = 0.04, *N* = 36,135) \[all rs12150660\], insulin secretion as assessed by oral glucose tolerance test-based measures of glucose, insulin and C-peptide at 30 and 120 min ( all *P* \> 0.14, *N* = 5771) or insulin resistance as measured by hyperinsulinaemic-euglycaemic clamps (*P* = 0.94, *N* = 1229) \[all rs1799941\].

DISCUSSION {#s3}
==========

Our study provides evidence that raised circulating SHBG levels reduce the risk of type 2 diabetes. Our results, together with those from the recent study by Ding *et al*. ([@DDP522C2]), provide insight into the role of sex hormones in the aetiology of type 2 diabetes. It has been known for some time that circulating SHBG levels are lower in people with type 2 diabetes compared with non-diabetic individuals, both in cross-sectional comparisons and prospectively. Despite this association, there has been considerable doubt as to the causal relevance of sex hormones in type 2 diabetes. The two genetic studies therefore add considerably to the argument that sex hormones are involved in the aetiology of the disease. This may have important implications for the treatment of diabetes or hypo- and hyper-androgenism in the two sexes.

There are several strengths to our study. First, genotypes are randomly distributed in ethnically homogenous populations, meaning our results are very unlikely to be confounded or biased or secondary to diabetes disease processes. Second, the statistical confidence of the association between the *SHBG* variant and type 2 diabetes is very strong---of approximately 1 million independent common variants in European genomes, we would only expect 20 to reach this level of statistical confidence by chance. Our results are consistent across 15 studies comprising 27 657 type 2 diabetic patients and 58 481 controls, with all but two studies showing an OR in the expected direction. Third, the ORs we observe between the *SHBG* rs1799941 SNP and type 2 diabetes are consistent with those expected from a triangulation approach. Fourth, the use of a SNP at the *SHBG* gene locus strongly associated with circulating SHBG levels means the association is very unlikely to be due to a pleiotropic effect of the variant on another pathway.

There are a few limitations to our study. Most notably we have not found any evidence for the mechanism behind the association between SHBG levels and type 2 diabetes. Despite the large numbers available, we did not observe any associations with various measures of insulin resistance or insulin secretion. This lack of association with intermediate type 2 diabetes traits is not inconsistent with the association with type 2 diabetes. The OR of 0.94 (equivalent to 1.06 for the SHBG lowering allele) is small and previous studies of variants of this magnitude have often not identified any associations with measures of insulin resistance or insulin secretion ([@DDP522C21]). This may in part be due to the reproducibility of measures based on insulin, which has a very short half life and fluctuates appreciably within individuals. We note, however, that the small effect size does not mean the finding has any less relevance to the question of aetiology, which relies only on the statistical confidence of the findings. A further caveat to our study is that we used a different and much smaller set of patients and controls to estimate the magnitude of the association between circulating SHBG levels and type 2 diabetes compared with the association between the *SHBG* SNP and type 2 diabetes. This difference meant that the estimated effect is very approximate and may be biased by the availability of data from previous publications. The confidence intervals of our estimated effect do not take into account the error in the estimate of the SNP-SHBG levels and so this adds further to the uncertainty of this calculation. Despite these concerns, the estimated and observed ORs for the *SHBG* SNP effect on type 2 diabetes were very similar.

There are some notable differences between our study and that of Ding *et al*. ([@DDP522C2]). While both studies support an association between *SHBG* SNPs and type 2 diabetes, the effect sizes are very different. Ding *et al*. report ORs of 1.52 (0.66 inverted) and 1.39 for rs6259 and rs6257, respectively. These ORs are similar to those for SNPs in the *TCF7L2* gene, which represent the most strongly associated SNPs in genome wide association studies of type 2 diabetes. There is no evidence of association between rs6259 (a non-synonymous SNP, D356N) and type 2 diabetes in data from 4549 cases and 5579 controls \[*P*=0.72, OR 1.02 \[0.92--1.12\], all of European ancestry\] ([@DDP522C22]), and this SNP appears to be less strongly associated with SHBG levels than rs1799941, based on data from previous studies ([@DDP522C23],[@DDP522C24]). The other SNP reported by Ding *et al*., rs6257, is not in HapMap but previously published data ([@DDP522C25]) indicates that rs1799941 and rs6257 are partially correlated and that rs1799941 drives the association with SHBG levels. These observations, together with our much larger sample size, suggest that the small OR of 0.94 is a closer reflection of the true effect size than that reported by Ding *et al*.

How might genetically lowered SHBG levels increase the risk of type 2 diabetes? Previous studies suggest that rs1799941 has different effects on total testosterone levels in men and women. Dunning *et al*. showed that the SHBG lowering allele at rs1799941 is not associated with total testosterone levels in postmenopausal women (*N* = 1975) ([@DDP522C23]). This means that women with genetically lower SHBG levels are exposed to proportionally more of the adverse effects of the biologically active unbound testosterone. In contrast, higher testosterone levels are thought to protect against adverse metabolic effects in men and Ahn *et al*. ([@DDP522C25]) showed that the SHBG raising allele at rs1799941 is strongly associated with higher total testosterone levels in men (*N* = 4678). This explanation is complicated by the fact that free testosterone levels are maintained in men by a strong feedback loop whereby luteinizing hormone (LH) production from the pituitary gland in the presence of low androgen levels stimulates testosterone production in the testes. This should mean that genetically lower SHBG levels will not greatly affect free testosterone levels in men. However, there is recent evidence that bound testosterone may be biologically active ([@DDP522C26]). If this is the case, then men with lower total testosterone due to lower SHBG will be exposed to less of the protective metabolic effects of androgens, despite similar levels of unbound testosterone.

There are additional implications of our results that require further study. First, our results and those of Ding *et al*. are not altered by adjustment or matching for BMI despite the fact that increased BMI and adiposity are correlated with reduced SHBG levels. This could mean that altered SHBG levels are part of the reason why increased BMI causally increases the risk of type 2 diabetes. Second, a SNP (rs6259) in the *SHBG* gene has been associated with prostate cancer and there is increasing evidence that there may be a casual link to the inverse association between prostate cancer and type 2 diabetes ([@DDP522C27]), although our results suggest that this requires additional studies of rs1799941 in prostate cancer ([@DDP522C28]).

In conclusion, a large type 2 diabetes case--control study provides strong statistical support for a role of SHBG and sex hormones in the aetiology of type 2 diabetes.

MATERIALS AND METHODS {#s4}
=====================

Our methods were based on the triangulation approach outlined in Figure [1](#DDP522F1){ref-type="fig"}. In summary we used (i) a common single nucleotide polymorphism (SNP) near the *SHBG* gene, rs1799941, previously shown to be very strongly associated with SHBG levels; (ii) 27 657 type 2 diabetes patients and 58 481 controls from 15 studies to test the association between this SNP and type 2 diabetes risk; (iii) data from six studies to estimate the magnitude of the association between SHBG levels and type 2 diabetes and (iv) existing data to calculate an approximate expected effect of the *SHBG* SNP on type 2 diabetes given the magnitude of the SNP versus SHBG levels association and the magnitude of the SHBG levels versus type 2 diabetes association.

Selection of a SNP strongly associated with SHBG levels {#s4a}
-------------------------------------------------------

Several genetic studies have established unequivocal evidence that common variation close to the *SHBG* gene influences circulating SHBG levels. We used previously published information to quantify the association between a SNP, rs1799941, 67 base pairs upstream of the *SHBG* gene and circulating SHBG levels. Several studies have shown consistent associations between rs1799941 and SHBG levels (*P* \< 1 × 10^−16^) ([@DDP522C23]--[@DDP522C25]). Each copy of the A allele is associated with a 0.20 SDs increase in SHBG levels, based on Finnish (NFBC66) and Italian (InCHIANTI) population-based studies, with similar effect sizes in men and women ([@DDP522C24]).

Observed association between *SHBG* SNP and type 2 diabetes risk {#s4b}
----------------------------------------------------------------

Through collaboration between 15 studies, we assembled a set of 27 657 cases and 58 481 controls. These studies varied in characteristics and ascertainment criteria and details are given in Table [1](#DDP522TB1){ref-type="table"}. All patients and controls were of European ancestry. The *SHBG* SNP rs1799941 was directly genotyped in all but three studies, two of which used a strongly correlated SNP (rs12150660 *r*^2^ = 0.9 with rs1799941), available as part of genome wide association data (FUSION1 and DGI), and a third used a mixture of directly genotyped and imputed data (Decode). Genotyping methods and quality control steps are given in [Supplementary Material, Table S1](http://hmg.oxfordjournals.org/cgi/content/full/ddp522/DC1). Individual studies calculated a per allele OR for the A allele at rs1799941, correcting for age, sex and BMI (except publicly available DGI data where cases and controls were matched for gender and BMI, and WTCCC samples, where data for BMI in controls was not available). The FUSION2 study additionally corrected for birth province and used 5 year age category instead of age. We next used the 'metan' command in STATAv10 to meta-analyse these results across all 15 studies. This function weighs all studies by the inverse of their variance (a function of SNP frequency and study size) to obtain a per allele estimate of the type 2 diabetes OR for all studies. We quote the OR effect of the SHBG raising allele, which, because raised SHBG levels are correlated with reduced risk of type 2 diabetes, we expected to be \<1.0, if SHBG levels are involved in the aetiology of type 2 diabetes. Given the different levels of SHBG in men and women we repeated analyses stratified by sex.

###### 

Characteristics of type 2 diabetes patients and controls from 15 studies

  Study                   Type 2 diabeties   Control                                                           
  ----------------------- ------------------ --------- ------- ------- ------ -------- ------- ------- ------- ------
  Men                                                                                                          
   WTCCC                  1334               50.15     9.08    30.43   5.32   1042     N/A     N/A     N/A     N/A
   Dundee                 2205               55.38     8.81    30.78   5.36   2283     59.98   11.41   27.16   3.95
   EFS-Y2D                102                40        5.45    30.63   4.9    861      32.7    5.97    26.59   3.87
   Danish                 2049               56.55     8.87    30.24   4.88   2252     47.06   9.16    26.11   3.52
   DGI^a^                 742                N/A       N/A     N/A     N/A    707      N/A     N/A     N/A     N/A
   Malmö CC               1641               56.76     11      29.09   4.9    1287     57.7    6.08    25.52   3.08
   FUSION1^a,b^           623                53.59     9.09    29.44   4.02   573      63.42   7.62    27.02   3.52
   KORA^b^                669                60.4      9.1     29.7    4.7    840      60.5    9       28      3.9
   Cambridgeshire CC^b^   346                63.4      7.9     28.7    3.8    343      63.7    7.9     27.1    3.5
   ADDITION/ELY^b^        553                60.2      7.5     32.3    5.4    725      61.2    9.2     27.1    3.9
   NDCCS^b^               3,575              66.4      10.6    29.3    4.8    3,038    58.9    9.1     26.3    3.1
   DeCODE                 832                55        12.1    29.7    4.9    7603     64.3    16.4    27.4    4.5
   FUSION2                646                58.3      8.82    30.23   4.96   724      57.45   7.58    26.74   3.41
   METSIM^c^              818                60.84     5.99    30.07   5.2    3372     57.98   6.4     26.25   3.46
   DIAGEN                 255                62.55     11.06   29.25   4.46   267      55.87   14.38   26.52   3.48
  Total                   16 390                                              25 917                           
  Women                                                                                                        
   WTCCC                  951                49.82     9.56    32.86   7.08   1039     N/A     N/A     N/A     N/A
   Dundee                 1666               56.36     8.98    32.82   6.83   2414     56.97   12.04   26.89   5.17
   EFS-YT2D               89                 37.88     7.18    34.14   7.78   901      30.44   5.25    23.97   4.39
   Danish                 1398               57.35     9.89    31.28   6.28   2607     46.81   8.97    25.08   4.39
   DGI^a^                 722                N/A       N/A     N/A     N/A    760      N/A     N/A     N/A     N/A
   Malmö CC               1150               59.46     11.89   30.46   6.13   2210     57.34   5.96    24.79   3.83
   FUSION1^a,b^           470                54.03     8.98    31.2    5.25   599      63.71   7.27    27.24   4.14
   KORA^b^                538                61.6      9.4     31.8    5.8    678      61.4    9.2     27.9    4.7
   Cambridgeshire CC^b^   202                63.3      7.9     31.6    6.8    191      63.5    7.7     27.8    5.1
   ADDITION/ELY^b^        339                62.9      6.4     34.2    6      885      60.5    9.1     27.1    5.4
   NDCCS^b^               2,481              67.1      11.4    30.8    6.5    3,390    57.8    9.3     25.9    4
   DeCODE                 582                55.2      12.7    30.6    6      16007    57.2    18.2    26.5    5.2
   FUSION2                437                61.09     7.45    31.75   5.76   463      60.92   7.34    27.14   4.6
   DIAGEN                 242                67.49     12.3    31.09   7      420      55.93   14.09   26.62   4.78
  Total                   11 267                                              32 564                           

N/A, clinical characteristics not available separated by sex. Age is the age at diagnosis for diabetic patients unless otherwise stated.

^a^DGI and FUSION1 studies used proxy SNP (*r*^2^ = 0.9) from GWAS data rs12150660.

^b^Age at recruitment given for these studies.

^c^METSIM is a study of men only.

Observed differences in SHBG levels between type 2 diabetes patients and controls {#s4c}
---------------------------------------------------------------------------------

SHBG levels are not routinely measured in type 2 diabetes patients and controls. Instead, we used data from type 2 diabetes studies (four of men only and three of women only) that had measured SHBG levels. These studies were men and women from the InCHIANTI study ([@DDP522C24]) and the cross-sectional studies published in the meta-analysis conducted by Ding *et al*. ([@DDP522C1]), for which we were able to retrieve mean and standard deviation measures of SHBG in cases and controls, were restricted to individuals of European ancestry, and had matched or corrected SHBG levels for body mass index or waist circumference. Details of these studies are given in Table [2](#DDP522TB2){ref-type="table"}. For each study, we tabulated six variables: number of cases, mean case SHBG levels, standard deviation of case SHBG levels, number of controls, mean control SHBG levels and standard deviation of control SHBG levels, using ngmol^−1^ as the units of SHBG. We performed an inverse variance weighted meta-analysis of these studies, both overall and within sexes, using the 'metan' command in STATAv10, to derive a standardized mean difference (SMD) of SHBG levels between type 2 diabetes cases and controls.

###### 

Details of SHBG levels in type 2 diabetes patients and normal glycaemic individuals in seven cross-sectional studies

                                          Type 2 diabetic patients   Controls                                                                                                              
  --------------------------------------- -------------------------- ------------- ------------------- -------- ------- ------ ------------- ------------------- ------------------------- -------
  Men                                                                                                                                                                                      
   Abate *et al*. ([@DDP522C34])^a^       33                         55 (9)        27.6 (5.0)          19.10    13.00   24     45 (9)        28.2 (7.6)          19.10                     13.00
   Svartberg *et al*. ([@DDP522C35])^b^   55                         N/A           N/A                 43.70    21.40   1364   N/A           N/A                 51.80                     22.00
   Kalme *et al*. ([@DDP522C36])^c^       109                        N/A           N/A                 63.20    29.23   152    N/A           N/A                 71.60                     25.20
   InCHIANTI^d^                           71                         72.0 (9.4)    27.80 (3.45)        85.12    46.83   476    66.6 (16.2)   26.91 (3.36)        87.22                     47.56
  TOTAL                                   268                                                                           2016                                                               
  SMD (95%CI)                                                                                                                                                    −0.218 (−0.360, −0.076)   
  Women                                                                                                                                                                                    
   Jayagopal *et al*. ([@DDP522C37])^e^   12                         62 (50--73)   31.6 (25.1--35.7)   38.80    18.20   11     56 (48--70)   32.0 (26.6--44.4)   42.20                     17.10
   Stoney *et al*. ([@DDP522C38])^f^      42                         64 (6.5)      28.8 (5.2)          27.80    20.50   42     63 (6.5)      28.9 (4.5)          40.30                     26.12
   InCHIANTI (4)                          67                         75.7 (9.8)    29.34 (5.05)        102.92   75.47   650    68.4 (15.8)   27.04 (4.58)        118.22                    85.17
  TOTAL                                   121                                                                           703                                                                
  SMD (95% CI)                                                                                                                                                   −0.264 (−0.475, −0.054)   

Data are from individuals of European ancestry matched or corrected for BMI or waist circumference. Women are postmenopausal.

SMD, standardized mean difference; N/A, not available from original publications.

^a^Controls selected to have the same range of BMI as cases. Controls include two individuals and cases include eight individuals of Hispanic ancestry.

^b^Svartberg *et al*., SHBG means and SDs are corrected for age and waist circumference.

^c^Kalme *et al*., SHBG means and SDs are corrected for BMI.

^d^InCHIANTI SHBG values are geometric values derived from lnSHBG levels corrected for age and BMI.

^e^Controls weight matched to cases. For BMI and age, median and range given.

^f^Stoney *et al*. controls selected to match cases for BMI and age.

Approximation of the expected association between *SHBG* SNP and type 2 diabetes risk {#s4d}
-------------------------------------------------------------------------------------

We used the estimates of the effect of rs1799941 on SHBG levels in (i) and the correlation between SHBG levels and type 2 diabetes estimated in (iii) to calculate an approximate expected effect of rs1799941 on type 2 diabetes, assuming that there is an aetiological association between SHBG levels and type 2 diabetes risk. We used the formula: where SD~A~ is the per allele effect of rs1799941 on circulating SHBG levels expressed as a standard deviation and SMD~B~ is the standardized mean difference (SMD) of SHBG levels between type 2 diabetes cases and controls. This approach has previously been described in the context of diabetes-related traits ([@DDP522C29]) and the rationale for the formula for approximating SMDs to ORs is described in more detail in Chinn *et al*. ([@DDP522C30]). The figure 1.81 is the scaling factor used to approximate ln(ORs) to and from standardized mean differences ([@DDP522C30]).

Associations between *SHBG* SNP and type 2 diabetes related traits {#s4e}
------------------------------------------------------------------

To test for associations between the SHBG SNP rs1799941 (or its close proxy rs12150660) and type 2 diabetes related traits, we used data from a variety of sources. For measures of fasting glucose and homeostatic model assessment (HOMA) based measures of insulin resistance, we used data from MAGIC of between 36 135 and 45 691 individuals, details of which are described in detail elsewhere ([@DDP522C31]). For measures of insulin secretion, we used 5771 individuals from the Danish study, details of which are described in detail elsewhere ([@DDP522C32]). For measures of whole body/peripheral insulin resistance, we used 1229 individuals from the RISC study ([@DDP522C33]). All statistical tests were performed using appropriate transformations (described in the relevant publications) and a per allele 1.d.f. test (in keeping with the additive effect of rs1799941 on SHBG levels).

SUPPLEMENTARY MATERIAL {#s5}
======================

[Supplementary Material is available at *HMG* online](http://hmg.oxfordjournals.org/cgi/content/full/ddp522/DC1).
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